Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate
- 1 March 1992
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 118 (3) , 235-237
- https://doi.org/10.1007/bf01410140
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.Journal of Clinical Oncology, 1991
- Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.Journal of Clinical Oncology, 1990
- Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.Journal of Clinical Oncology, 1989
- DIRECT DIFFUSION OF CIS-DIAMMINEDICHLOROPLATINUM(II) IN INTRAPERITONEAL RAT-TUMORS AFTER INTRAPERITONAL CHEMOTHERAPY - A COMPARISON WITH SYSTEMIC CHEMOTHERAPY1989
- CIS-DIAMMINEDICHLOROPLATINUM(II) ACCUMULATION IN SENSITIVE AND RESISTANT HUMAN OVARIAN-CARCINOMA CELLS1988
- Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavityCancer Treatment Reviews, 1986
- In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.1985
- High-Dose Cisplatin in Hypertonic SalineAnnals of Internal Medicine, 1984
- PHARMACOKINETICS OF ADRIAMYCIN AND TISSUE PENETRATION IN MURINE OVARIAN-CANCER1979
- PHARMACOKINETIC RATIONALE FOR PERITONEAL DRUG ADMINISTRATION IN TREATMENT OF OVARIAN CANCER1978